Showing results (2371-2380 of 5,702) with videos related to

Sort By:
Pageof 571
The Oncologist|June 27, 2019
Oxaliplatin plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO-CLASSIC StudyYiyi Yu, Yong Fang, Zhenbin Shen, et al.
The Oncologist|June 29, 2019
Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial ChemoembolizationYanqin Wu, Wenzhe Fan, Miao Xue, et al.
The Oncologist|September 27, 2018
Perceptions of Oncologists About Sharing Clinic Notes with PatientsNadine J McCleary, Michael J Healey, Shicheng Weng, et al.
The Oncologist|September 28, 2018
Prognostic Nomogram Based on Histological Characteristics of Fibrotic Tumor Stroma in Patients Who Underwent Curative Resection for Intrahepatic CholangiocarcinomaChu-Yu Jing, Yi-Peng Fu, Jin-Long Huang, et al.
The Oncologist|September 28, 2018
Cosmetic Consequences of Breast-Conserving Treatment for Breast Cancer: Something Worth Talking AboutAngelique Brands-Appeldoorn, Sabrina Maaskant-Braat, Karin Schenk, et al.
The Oncologist|September 30, 2018
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent GlioblastomaAlba A Brandes, Miguel Gil-Gil, Frank Saran, et al.
The Oncologist|July 12, 2019
Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2)Ricarda Merten, Oliver Ott, Marlen Haderlein, et al.
The Oncologist|July 12, 2019
Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort StudyWilliam D Leslie, Suzanne N Morin, Lisa M Lix, et al.
The Oncologist|July 1, 2017
Appendiceal Mucinous Neoplasms: Diagnosis and ManagementWalid L Shaib, Rita Assi, Ali Shamseddine, et al.
The Oncologist|April 6, 2023
Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus BevacizumabTaito Fukushima, Manabu Morimoto, Satoshi Kobayashi, et al.
Pageof 571